Anaphylaxis News and Research

RSS

Anaphylaxis is an acute multi-system severe type I hypersensitivity reaction. Due in part to the variety of definitions, between 1% and 15% of the population of the United States can be considered "at risk" for having an anaphylactic reaction if they are exposed to one or more allergens. Of those people who actually experience anaphylaxis, up to 1% may die as a result.

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced the initiation of a global phase III clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed CD30-positive mature T-cell lymphoma (MTCL) patients, including patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphomas.

28 Jan 2013

Sanofi Canada announces new option for emergency treatment of anaphylaxis

Sanofi Canada announces a new option for the emergency treatment of anaphylaxis. Allerject is the first and only 'talking' epinephrine auto-injector in Canada.

28 Jan 2013

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.

28 Jan 2013

Results from Amgen’s Neulasta plus bevacizumab Phase 3 trial on colorectal cancer

Amgen announced today results from Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES), a Phase 3 trial which evaluated Neulasta (pegfilgrastim) in 845 patients receiving FOLFOX or FOLFIRI and bevacizumab for the first-line treatment of locally-advanced or metastatic colorectal cancer.

28 Jan 2013

Single dose of seasonal flu vaccine is safe for egg allergic children

Egg allergic children, including those with a history of anaphylaxis to egg, can safely receive a single dose of the seasonal influenza vaccine, according to a new study from the University of Michigan.

23 Jan 2013

Elan, Biogen Idec submit applications to FDA and EMA for updation of TYSABRI labels

Today Biogen Idec and Elan Corporation, plc announced that they have submitted applications to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) requesting updates to the TYSABRI (natalizumab) labels.

16 Jan 2013

Merck’s resubmission of the NDA for suggammadex sodium injection accepted for review by the FDA

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the resubmission of the New Drug Application (NDA) for sugammadex sodium injection has been accepted for review by the U.S. Food and Drug Administration (FDA). Merck expects the FDA’s review to be completed in the first half of 2013.

7 Jan 2013

AMAG seeks FDA sNDA approval for Feraheme Injection

AMAG Pharmaceuticals, Inc. today announced that it has submitted a supplemental new drug application (sNDA) to the United States Food and Drug Administration (FDA) for Feraheme (ferumoxytol) Injection for Intravenous (IV) use.

25 Dec 2012

GSK receives FDA approval for FLUARIX QUADRIVALENT to treat seasonal flu

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved FLUARIX QUADRIVALENT (Influenza Virus Vaccine) for the immunisation of children (three years and older) and adults to help prevent disease caused by seasonal influenza (flu) virus subtypes A and type B contained in the vaccine.

17 Dec 2012

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

AMAG Pharmaceuticals, Inc. today announced that new data from two pivotal phase III clinical trials were presented at the American Society of Hematology's (ASH) annual meeting in Atlanta, Georgia.

11 Dec 2012

New survival results from Genentech’s Perjeta Phase III combination study on HER2-positive mBC

Genentech, a member of the Roche Group, today announced updated survival results from the Phase III CLEOPATRA study, which showed that the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy significantly extended the lives (overall survival) of people with previously untreated HER2-positive metastatic breast cancer (mBC), compared to Herceptin, chemotherapy and placebo.

10 Dec 2012

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

AstraZeneca today announced the presentation of important new data from studies of FASLODEX (fulvestrant) Injection at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium taking place from 4-8 December at the Henry B. Gonzalez Convention Center, San Antonio, Texas.

5 Dec 2012

New study finds chemicals used for water purification can lead to food allergies

Food allergies are on the rise, affecting 15 million Americans. And according to a new study published in the December issue of Annals of Allergy, Asthma and Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI), pesticides and tap water could be partially to blame.

3 Dec 2012

Tdap well tolerated in over-65s

Off-label use of tetanus–diptheria–acellular pertussis vaccine in senior patients results in no more adverse events than the tetanus and diphtheria vaccine, a US study shows.

30 Nov 2012

FDA grants Seattle Genetics orphan drug designation for ADCETRIS to treat mycosis fungoides

Seattle Genetics, Inc. announced today that ADCETRIS (brentuximab vedotin) has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of mycosis fungoides (MF). MF is the most common type of cutaneous T-cell lymphoma (CTCL).

26 Nov 2012

Lone star tick causes alpha-gal meat sensitivity in regional population

Meat lovers living in the central and southern regions of the country might be opting for a vegetarian lifestyle if meat comes with an unwanted side of a life-threatening allergic reaction. According to a study presented at the Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology (ACAAI), the lone star tick inhabiting these regions is the primary reason for what's known as a meat induced alpha-gal allergic reaction.

9 Nov 2012

Only 15% of patients with anaphylaxis receive epinephrine from paramedics

Epinephrine is the first line of treatment for patients suffering from anaphylaxis, a life-threatening allergic reaction.

9 Nov 2012

More than half of allergic children can tolerate baked hen's eggs

Avoiding sweet treats like pumpkin bread and cookies this holiday season might not be necessary for children with egg allergies. New studies presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting found 56 percent of allergic children can tolerate baked hen's egg, while 55 percent outgrow their egg allergy entirely.

9 Nov 2012

High family income, hygiene habits can increase risk of peanut allergies in children

Peanut allergies are rising among American children and one reason might be due to economic status. According to a new study presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting, greater rates of peanut allergy are found in families with higher economic status. This supports the "hygiene hypothesis" of many allergists.

9 Nov 2012

Women more likely to develop spice allergy

Imagine a world where you could never dine away from home, wear makeup, smell of sweet perfumes or eat a large percentage of food on store shelves. According to allergists at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting that is kicking off today in Anaheim, Calif., that is the world for 2 to 3 percent of individuals living with a spice allergy.

8 Nov 2012

Anaphylaxis News and Research

Further Reading

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Sanofi Canada announces new option for emergency treatment of anaphylaxis

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

Results from Amgen’s Neulasta plus bevacizumab Phase 3 trial on colorectal cancer

Single dose of seasonal flu vaccine is safe for egg allergic children

Elan, Biogen Idec submit applications to FDA and EMA for updation of TYSABRI labels

Merck’s resubmission of the NDA for suggammadex sodium injection accepted for review by the FDA

AMAG seeks FDA sNDA approval for Feraheme Injection

GSK receives FDA approval for FLUARIX QUADRIVALENT to treat seasonal flu

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

New survival results from Genentech’s Perjeta Phase III combination study on HER2-positive mBC

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

New study finds chemicals used for water purification can lead to food allergies

Tdap well tolerated in over-65s

FDA grants Seattle Genetics orphan drug designation for ADCETRIS to treat mycosis fungoides

Lone star tick causes alpha-gal meat sensitivity in regional population

Only 15% of patients with anaphylaxis receive epinephrine from paramedics

More than half of allergic children can tolerate baked hen's eggs

High family income, hygiene habits can increase risk of peanut allergies in children

Women more likely to develop spice allergy

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News